NGAL Reference a literatura

Reference a literatura

Immunochemical Determination of Monomer, Homodimer and Total Neutrophil Gelatinase-Associated Lipocalin

15 / 11 /2012 Kristian Bangert, Niels Rosenkilde, Jakob Ploug Jørgensen, Alexandra Baer and Lars Otto Uttenthal. BioPorto Diagnostics A/S, Gentofte, Denmark

ELISAs specific for monomer and homodimer forms of NGAL were developed, as well as an ELISA for “total” NGAL that measures monomer and homodimer equally on a mass basis. NGAL monomer is the major form of NGAL in urine from ICU patients, while the occurrence of NGAL homodimer is low and sporadic. The NGAL Test™, a particle-enhanced turbidimetric immunoassay for central laboratory equipment, gave results for urine samples that were comparable with those obtained by the ELISAs for monomer and “total” NGAL. The occasional presence of low levels of NGAL homodimer has little impact on the interpretation of results obtained with monomer-reactive, homodimer cross-reactive NGAL assays.

Early detection of Acute Kidney Injury in sepsis: how about NGAL?

03 / 09 / 2012 Dr W. Huber, Dr B. Saugel, Dr R. M Schmid and Dr A. Wacker-Gussmann

Sepsis frequently results in acute kidney injury (AKI). Although AKI markedly contributes to mortality in sepsis, its diagnosis is frequently delayed due to limitations of current biomarkers of renal impairment. Neutrophil-gelatinase-associated lipocalin (NGAL) has been demonstrated to be a biomarker of early AKI. This review analyses the potential use of NGAL in sepsis.

Why use NGAL?

28 / 05 / 2012 The title speaks for itself – why keep guessing about something as serious as AKi when you can get vital information about your patient’s status from the earliest responding AKi marker, NGAL?

Quantitative determination of human plasma and urine Neutrophil Gelatinase Associated Lipocalin (NGAL) validation of an automated turbidimetric immunoassay

23 / 05 / 2011 Christensen PH. Holm SS. Kjøller C. Just T. and Heerfordt L. Reagent Partnership Division, Dako Denmark A/S, Produktionsvej 42, DK-2600, Denmark.

Changing the diagnosis of acute kidney injury

2011 Key abstracts (selected by BioPorto)

Changing the diagnosis and management of acute kidney injury

2011 BioPorto

NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers and shows a proportionate response to injury. NGAL thus permits the early diagnosis and prognostic stratification of AKI and enables new specific therapies to be developed.

Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury

2010 Kümpers et al. Critical Care 2010, 14:R9

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising novel biomarker that correlates with the severity and outcome of acute kidney injury (AKI). However, its prognostic utility during the late course of AKI, especially in patients that require renal replacement therapy (RRT) remains unknown. The aim of this study was to evaluate the predictive value of serum NGAL in patients with established AKI at inception of RRT in the intensive care unit (ICU).

BioPorto’s NGAL test approved for use by leading U.S. reference laboratory

12 / 08 / 2010 BioPorto. Announcement no. 07

Mayo Medical Laboratories (Rochester, Minnesota, U.S.A.) are now offering BioPorto’s NGAL test for the diagnosis of acute renal injury.

Mayo’s implementation of NGAL testing is a decisive step in BioPorto’s entry onto the considerable routine diagnostic market in the U.S.A. At present there is no FDA (Food and Drug Administration) approved NGAL test on the market. That Mayo Medical Laboratories can nevertheless offer BioPorto’s test is due to the process of so-called home-brew approval, whereby the laboratory itself validates the test and takes responsibility for its diagnostic use.

Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity?

14 / 01 / 2010 Anna Wasilewska & Walentyna Zoch-Zwierz & Katarzyna Taranta-Janusz & Joanna Michaluk-Skutnik, Pediatr Nephrol (2010) 25:889–897

The aim of work was to investigate whether serum and urinary neutrophil gelatinase-associated lipocalin (sNGAL and uNGAL, respectively) are potential biomarkers of early cyclosporine A (CsA) nephrotoxicity in steroid-dependent nephrotic children (SDNS). The study group (I) consisted of 19 children with SDNS aged 9.46± 5.52 years treated with CsA. The children were examined four times: at proteinuria relapse, prior to CsA treatment, then after 3, 6, and 12 months of CsA treatment. The control group (II) consisted of 18 healthy children aged 3–15 years. A commercial enzyme-linked immunosorbent assay method was used to measure NGAL concentration.

Emerging biomarkers for Acute Kidney Injury

30 / 05 / 2009 Dr Prasad Devarajan, As published in CLI April/May 2009

Early diagnosis of AKI currently depends on detection of reduced kidney function by the rise in serum creatinine concentration, an unreliable measure in the acute setting. This article discusses the pros and cons of emerging early biomarkers which may prove useful.

NGAL is a marker for renal replacement therapy requirement

19 / 08 / 2008 K. Bangert, M. Ghiglione and L.O. Uttenthal

Renal expression of neutrophil gelatinase-associated lipocalin (NGAL) increses dramatically after renal ischemia orexposure to nephrotoxic agents. The usefulness of NGAL as a marker of renal injury leading to acute renal failure (ARF) has previously been demonstrated in patient groups that have few confounding factors such as sepsis or cancer. The aim of the present study was to test the usefulness of NGAL levels for predicting a requirement for renal replacement therapy (RRT) in unselected critically ill patients admitted to intensive care.

© 2010, Lab Mark


Giant InteractiveGiant Interactive